The role of B lymphocyte stimulator in B cell biology: Implications for the treatment of lupus

Lupus

Volumn 22, Issue 4, 2013, Pages 350-360

  Scholz, J L ^a   Oropallo, M A ^a   Sindhava, V ^a   Goenka, R ^a   Cancro, M P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B cell activating factor; B lymphocyte stimulator; belimumab; peripheral tolerance; toll like receptor

Indexed keywords

B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; BELIMUMAB;

ARTICLE; B LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL SELECTION; CELL SURVIVAL; CYTOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL DIFFERENTIATION; DRUG APPROVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84875944644     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312469453     Document Type: Article

References (166)

1. Zhao LD, Li Y, Smith MF, et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus. 2013 ; 19: 1534-1549
2. Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther. 2013 ; 12: 111-111
3. Landolt-Marticorena C, Wither R, Reich H, et al. Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. J Rheumatol. 2011 ; 38: 642-651
4. Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A. 2000 ; 97: 3370-3375
5. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: Fast-forward on autoimmunity and signaling. Curr Opin Immunol. 2007 ; 19: 327-336
6. Fletcher CA, Groom JR, Woehl B, Leung H, Mackay C, Mackay F. Development of autoimmune nephritis in genetically asplenic and splenectomized BAFF transgenic mice. J Autoimmun. 2011 ; 36: 125-134
7. Stohl W, Jacob N, Guo S, Morel L. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum. 2013 ; 62: 2432-2442
8. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999 ; 190: 1697-1710
9. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009 ; 119: 1066-1073
10. Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol. 2013 ; 22: 732-739
11. Stohl W, Scholz JL, Cancro MP. Targeting BLyS in rheumatic disease: The sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol. 2011 ; 23: 305-310
12. Lamore R III, Parmar S, Patel K, Hilas O. Belimumab (benlysta): A breakthrough therapy for systemic lupus erythematosus. P & T. 2012 ; 37: 212-226
13. Miller JP, Stadanlick JE, Cancro MP. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol. 2006 ; 176: 6405-6410
14. Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res. 2011 ; 317: 1270-1277
15. Scholz JL, Luning Prak ET, Cancro MP. Targeting the BLyS family in autoimmunity: A tale of mouse and man. Clin Invest. 2011 ; 1: 951-967
16. Yurasov S, Nussenzweig MC. Regulation of autoreactive antibodies. Curr Opin Rheumatol. 2007 ; 19: 421-426
17. Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv Immunol. 2007 ; 95: 83-110
18. Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature. 1991 ; 349: 331-334
19. Hannum LG, Ni D, Haberman AM, Weigert MG, Shlomchik MJ. A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: Implications for the origins of autoantibodies in autoimmune disease. J Exp Med. 1996 ; 184: 1269-1278
20. Nashi E, Wang Y, Diamond B. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol. 2013 ; 42: 543-550
21. Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther. 2011 ; 13: 243-254-243-254
22. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol. 2008 ; 20: 632-638
23. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009 ; 9: 491-502
24. Oropallo MA, Kiefer K, Marshak-Rothstein A, Cancro MP. Beyond transitional selection: New roles for BLyS in peripheral tolerance. Drug Dev Res. 2011 ; 72: 779-787
25. Cancro MP. The BLyS family of ligands and receptors: An archetype for niche-specific homeostatic regulation. Immunol Rev. 2004 ; 202: 237-249
26. Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol. 2006 ; 18: 263-275
27. Huard B, McKee T, Bosshard C, et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest. 2008 ; 118: 2887-2895
28. Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011 ; 244: 115-133
29. Crowley JE, Scholz JL, Quinn WJ III, et al. Homeostatic control of B lymphocyte subsets. Immunol Res. 2008 ; 42: 75-83
30. Treml JF, Hao Y, Stadanlick JE, Cancro MP. The BLyS family: Toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys. 2009 ; 53: 1-16
31. Stadanlick JE, Kaileh M, Karnell FG, et al. Tonic B cell antigen receptor signals supply an NF-kappa B substrate for prosurvival BLyS signaling. Nat Immunol. 2008 ; 9: 1379-1387
32. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008 ; 180: 3655-3659
33. O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004 ; 199: 91-98
34. Scholz JL, Crowley JE, Tomayko MM, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A. 2008 ; 105: 15 517-15522
35. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 ; 64: 2328-2337
36. Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012; 39: 1632-1640.
37. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med. 2003 ; 198: 937-945
38. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol. 2006 ; 18: 305-317
39. Bossen C, Tardivel A, Willen L, et al. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol. 2011 ; 41: 787-797
40. Bossen C, Cachero TG, Tardivel A, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood. 2008 ; 111: 1004-1012
41. Kalinina O, Doyle-Cooper CM, Miksanek J, Meng W, Prak EL, Weigert MG. Alternative mechanisms of receptor editing in autoreactive B cells. Proc Natl Acad Sci U S A. 2011 ; 108: 7125-7130
42. Pelanda R, Torres RM. Receptor editing for better or for worse. Curr Opin Immunol. 2006 ; 18: 184-190
43. Pelanda R, Torres RM. Central B-cell tolerance: Where selection begins. Cold Spring Harb Perspect Biol. 2012 ; 4: a007146 - a007146
44. Osmond DG. Proliferation kinetics and the lifespan of B cells in central and peripheral lymphoid organs. Curr Opin Immunol. 1991 ; 3: 179-185
45. Allman DM, Ferguson SE, Lentz VM, Cancro MP. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol. 1993 ; 151: 4431-4444
46. Osmond DG. The turnover of B-cell populations. Immunol Today. 1993 ; 14: 34-37
47. Rolink AG, Andersson J, Melchers F. Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. Eur J Immunol. 1998 ; 28: 3738-3748
48. Verkoczy LK, Martensson AS, Nemazee D. The scope of receptor editing and its association with autoimmunity. Curr Opin Immunol. 2004 ; 16: 808-814
49. Azulay-Debby H, Melamed D. B cell receptor editing in tolerance and autoimmunity. Front Biosci. 2007 ; 12: 2136-2147
50. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol. 2002 ; 168: 5993-5996
51. Loder F, Mutschler B, Ray RJ, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med. 1999 ; 190: 75-89
52. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol. 2001 ; 167: 6834-6840
53. Smith SH, Reth M. Perspectives on the nature of BCR-mediated survival signals. Mol Cell. 2004 ; 14: 696-697
54. Monroe JG, Dorshkind K. Fate decisions regulating bone marrow and peripheral B lymphocyte development. Adv Immunol. 2007 ; 95: 1-50
55. Wang H, Clarke SH. Evidence for a ligand-mediated positive selection signal in differentiation to a mature B cell. J Immunol. 2003 ; 171: 6381-6388
56. Monroe JG, Bannish G, Fuentes-Panana EM, et al. Positive and negative selection during B lymphocyte development. Immunol Res. 2003 ; 27: 427-442
57. Harless SM, Lentz VM, Sah AP, et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol. 2001 ; 11: 1986-1989
58. Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000 ; 192: 129-135
59. Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001 ; 11: 1547-1552
60. Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000 ; 192: 1453-1466
61. Lentz VM, Cancro MP, Nashold FE, Hayes CE. Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. J Immunol. 1996 ; 157: 598-606
62. Lentz VM, Hayes CE, Cancro MP. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. J Immunol. 1998 ; 160: 3743-3747
63. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol. 2004 ; 173: 2245-2252
64. Stadanlick JE, Cancro MP. BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol. 2008 ; 20: 158-161
65. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004 ; 20: 441-453
66. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004 ; 20: 785-798
67. Hondowicz BD, Alexander ST, Quinn WJ III, et al. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int Immunol. 2007 ; 19: 465-475
68. Cancro MP. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol. 2009 ; 9: 657-661
69. Sutter JA, Kwan-Morley J, Dunham J, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol. 2008 ; 126: 282-290
70. Palanichamy A, Barnard J, Zheng B, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009 ; 182: 5982-5993
71. Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007 ; 122: 139-145
72. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006 ; 54: 613-620
73. Warnatz K, Salzer U, Rizzi M, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A. 2009 ; 106: 13 945-13950
74. Carter RH, Zhao H, Liu X, et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum. 2005 ; 52: 3943-3954
75. Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2012 ; 188: 497-503
76. Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov. 2011 ; 10: 335-336
77. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005 ; 201: 703-711
78. Yurasov S, Tiller T, Tsuiji M, et al. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med. 2006 ; 203: 2255-2261
79. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum. 2003 ; 48: 3475-3486
80. Dillon SR, Harder B, Lewis KB, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2013 ; 12: R48 - R48
81. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004 ; 50: 3580-3590
82. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008 ; 58: 2453-2459
83. Treml LS, Quinn WJ III, Treml JF, Scholz JL, Cancro MP. Manipulating B cell homeostasis: A key component in the advancement of targeted strategies. Arch Immunol Ther Exp (Warsz). 2008 ; 56: 153-164
84. Scholz JL, Cancro MP. Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunol Lett. 2012 ; 143: 2-8
85. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis. 2008 ; 67: 1011-1016
86. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007 ; 66: 700-703
87. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis. 2006 ; 65: S34 - S36
88. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003 ; 301: 1374-1377
89. Zeng D, Lee MK, Tung J, Brendolan A, Strober S. Cutting edge: A role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol. 2000 ; 164: 5000-5004
90. Grimaldi CM, Michael DJ, Diamond B. Cutting edge: Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol. 2001 ; 167: 1886-1890
91. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol. 2007 ; 178: 2415-2420
92. Herve M, Isnardi I, Ng YS, et al. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med. 2007 ; 204: 1583-1593
93. Chan TD, Brink R. Affinity-based selection and the germinal center response. Immunol Rev. 2012 ; 247: 11-23
94. Elgueta R, De Vries VC, Noelle RJ. The immortality of humoral immunity. Immunol Rev. 2013 ; 236: 139-150
95. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012 ; 247: 52-63
96. Zaheen A, Martin A. Activation-induced cytidine deaminase and aberrant germinal center selection in the development of humoral autoimmunities. Am J Pathol. 2011 ; 178: 462-471
97. Wang H, Shlomchik MJ. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J Exp Med. 1999 ; 190: 639-649
98. Hao Z, Duncan GS, Seagal J, et al. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity. 2008 ; 29: 615-627
99. Nanan R, Strobel P, Haas JP, Marx A, Kreth HW. Autoimmune lymphoproliferative syndrome associated with severe humoral immunodeficiency and monoclonal gammopathy. Ann Hematol. 2002 ; 81: 332-335
100. Infante AJ, Britton HA, DeNapoli T, et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J Pediatr. 1998 ; 133: 629-633
101. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet. 1999 ; 64: 1002-1014
102. Van Eijk M, Defrance T, Hennino A, De Groot C. Death-receptor contribution to the germinal-center reaction. Trends Immunol. 2001 ; 22: 677-682
103. Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A. 2004 ; 101: 3903-3908
104. Vora KA, Wang LC, Rao SP, et al. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol. 2003 ; 171: 547-551
105. Rahman ZS, Rao SP, Kalled SL, Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med. 2003 ; 198: 1157-1169
106. Rahman ZS, Manser T. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J Immunol. 2004 ; 173: 6179-6188
107. Miller DJ, Hanson KD, Carman JA, Hayes CE. A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte-deficient A/WySnJ mice. Eur J Immunol. 1992 ; 22: 373-379
108. Castigli E, Wilson SA, Elkhal A, Ozcan E, Garibyan L, Geha RS. Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation. J Allergy Clin Immunol. 2007 ; 120: 885-891
109. Mantchev GT, Cortesao CS, Rebrovich M, Cascalho M, Bram RJ. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J Immunol. 2007 ; 179: 2282-2288
110. He B, Santamaria R, Xu W, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol. 2013 ; 11: 836-845
111. Von Bulow GU, Van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity. 2001 ; 14: 573-582
112. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007 ; 179: 7276-7286
113. Winter O, Moser K, Mohr E, et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood. 2013 ; 116: 1867-1875
114. Belnoue E, Tougne C, Rochat AF, Lambert PH, Pinschewer DD, Siegrist CA. Homing and adhesion patterns determine the cellular composition of the bone marrow plasma cell niche. J Immunol. 2012 ; 188: 1283-1291
115. Varfolomeev E, Kischkel F, Martin F, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol. 2004 ; 24: 997-1006
116. Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest. 2006 ; 116: 724-734
117. Carbonatto M, Yu P, Bertolino M, et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci. 2008 ; 105: 200-210
118. Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008 ; 111: 2755-2764
119. Treml LS, Crowley JE, Cancro MP. BLyS receptor signatures resolve homeostatically independent compartments among naive and antigen-experienced B cells. Semin Immunol. 2006 ; 18: 297-304
120. Pallikkuth S, Kanthikeel SP, Silva SY, Fischl M, Pahwa R, Pahwa S. Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients. J Allergy Clin Immunol. 2011 ; 128: 1279-1285
121. Ettinger R, Sims GP, Robbins R, et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol. 2007 ; 178: 2872-2882
122. Anderson SM, Tomayko MM, Shlomchik MJ. Intrinsic properties of human and murine memory B cells. Immunol Rev. 2006 ; 211: 280-294
123. Reynaud CA, Descatoire M, Dogan I, Huetz F, Weller S, Weill JC. IgM memory B cells: A mouse/human paradox. Cell Mol Life Sci. 2012 ; 69: 1625-1634
124. Tangye SG, Tarlinton DM. Memory B cells: effectors of long-lived immune responses. Eur J Immunol. 2009 ; 39: 2065-2075
125. Pauli NT, Henry Dunand CJ, Wilson PC. Exploiting human memory B cell heterogeneity for improved vaccine efficacy. Front Immunol. 2011 ; 2: 77: 1-12
126. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity. 2007 ; 26: 205-213
127. Huang W, Moisini I, Bethunaickan R, et al. BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol. 2011 ; 187: 6571-6580
128. Tiller T, Kofer J, Kreschel C, et al. Development of self-reactive germinal center B cells and plasma cells in autoimmune Fc gammaRIIB-deficient mice. J Exp Med. 2013 ; 207: 2767-2778
129. Vuyyuru R, Mohan C, Manser T, Rahman ZS. The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints. J Immunol. 2009 ; 183: 5716-5727
130. Cappione A III, Anolik JH, Pugh-Bernard A, et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest. 2005 ; 115: 3205-3216
131. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003 ; 48: 1332-1342
132. Mietzner B, Tsuiji M, Scheid J, et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci U S A. 2008 ; 105: 9727-9732
133. Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 2008 ; 58: 1762-1773
134. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2013 ; 62: 542-552
135. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest. 2003 ; 112: 1506-1520.m
136. Calero I, Nieto JA, Sanz I. B cell therapies for rheumatoid arthritis: Beyond B cell depletion. Rheum Dis Clin North Am. 2013 ; 36: 325-343
137. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2013 ; 62: 222-233
138. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005 ; 44: 1542-1545
139. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2013 ; 62: 201-210
140. Chugh PK. Lupus: novel therapies in clinical development. Eur J Intern Med. 2012 ; 23: 212-218
141. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 ; 56: 4142-4150
142. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009 ; 18: 547-555
143. Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, Defrance T. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol. 2007 ; 178: 7779-7786
144. Martin F, Oliver AM, Kearney JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity. 2001 ; 14: 617-629
145. Guinamard R, Okigaki M, Schlessinger J, Ravetch JV. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol. 2000 ; 1: 31-36
146. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006 ; 6: 823-835
147. Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med. 2007 ; 204: 1959-1971
148. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997 ; 388: 394-397
149. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001 ; 1: 135-145
150. Booth J, Wilson H, Jimbo S, Mutwiri G. Modulation of B cell responses by Toll-like receptors. Cell Tissue Res. 2011 ; 343: 131-140
151. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001 ; 413: 732-738
152. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004 ; 303: 1529-1531
153. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000 ; 408: 740-745
154. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004 ; 303: 1526-1529
155. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002 ; 416: 603-607
156. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003 ; 19: 837-847
157. Uccellini MB, Busconi L, Green NM, et al. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J Immunol. 2008 ; 181: 5875-5884
158. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005 ; 202: 1171-1177
159. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006 ; 25: 417-428
160. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med. 2005 ; 202: 321-331
161. Nickerson KM, Christensen SR, Shupe J, et al. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol. 2013 ; 184: 1840-1848
162. Cohen PL, Caricchio R, Abraham V, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med. 2002 ; 196: 135-140
163. Hanayama R, Tanaka M, Miyasaka K, et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science. 2004 ; 304: 1147-1150
164. Treml LS, Carlesso G, Hoek KL, et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol. 2007 ; 178: 7531-7539
165. Kim J, Gross JA, Dillon SR, Min JK, Elkon KB. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation. Autoimmunity. 2011 ; 44: 69-81
166. Obukhanych TV, Nussenzweig MC. T-independent type II immune responses generate memory B cells. J Exp Med. 2006 ; 203: 305-310